https://www.pharmaceutical-technology.com/data-insights/brexucabtagene-autoleucel-gilead-sciences-refractory-acute-myeloid-leukemia-likelihood-of-approval/
Brexucabtagene autoleucel is under clinical development by Gilead Sciences and currently in Phase II for Refractory Acute Myeloid Leukemia.
acute myeloid leukemiabrexucabtagene autoleucelgilead sciencesrefractory